Top Page
Wellnex Life Ltd
(Sydney:WNX)
Wellnex Life Ltd (WNX) vs. iShares MSCI Australia ETF (EWA)
Wellnex Life Ltd Business Overview & Revenue Model
Wellnex Life Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 23.63M | 23.63M | 16.93M | 27.89M | 18.61M | 1.20M |
| Gross Profit | 6.88M | 6.88M | -776.00K | 4.75M | 4.50M | -165.00K |
| EBITDA | -6.62M | -6.62M | -10.57M | -6.82M | -6.35M | -18.41M |
| Net Income | -15.60M | -15.60M | -13.74M | -13.85M | -7.45M | -24.69M |
Balance Sheet | ||||||
| Total Assets | 27.84M | 27.84M | 30.92M | 15.04M | 19.61M | 10.42M |
| Cash, Cash Equivalents and Short-Term Investments | 497.00K | 497.00K | 903.00K | 322.00K | 3.18M | 7.78M |
| Total Debt | 5.45M | 5.45M | 10.67M | 6.95M | 7.86M | 9.31M |
| Total Liabilities | 16.59M | 16.59M | 24.86M | 14.45M | 15.25M | 10.67M |
| Stockholders Equity | 11.25M | 11.25M | 6.06M | 594.00K | 4.36M | -249.00K |
Cash Flow | ||||||
| Free Cash Flow | -666.00K | -666.00K | -6.82M | -6.19M | -8.65M | -5.17M |
| Operating Cash Flow | -666.00K | -666.00K | -6.82M | -6.19M | -8.61M | -4.38M |
| Investing Cash Flow | -8.29M | -8.29M | -13.42M | -2.20M | -3.65M | 9.45M |
| Financing Cash Flow | 8.55M | 8.55M | 20.82M | 5.53M | 7.66M | 1.55M |
Wellnex Life Ltd Technical Analysis
Wellnex Life Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
45 Neutral | AU$23.34M | -5.75 | -29.43% | ― | 102.21% | 69.47% | |
43 Neutral | AU$27.14M | 35.22 | ― | ― | 6.76% | ― | |
41 Neutral | AU$7.07M | ― | -60.84% | ― | -18.70% | 20.83% | |
38 Underperform | €12.24M | -0.35 | -184.71% | ― | 39.53% | 49.99% | |
31 Underperform | AU$4.07M | -0.58 | ― | ― | -21.84% | 79.99% |
Wellnex Life Ltd Corporate Events
Wellnex Life Limited announced that they are working towards finalizing a repayment schedule for a loan provided by Zack Bozinovski and his wife, with an expected conclusion by 7 November 2025. This update indicates ongoing negotiations and potential financial implications for Wellnex, as the company seeks to resolve outstanding financial commitments, which could impact its financial stability and stakeholder confidence.
The most recent analyst rating on (AU:WNX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life Limited has announced its upcoming Annual General Meeting, scheduled for November 27, 2025, in Port Melbourne, Australia. The company also shared that Vivienne Zhang, the Chief Financial Officer, will not stand for election as a director, preferring to focus on her CFO responsibilities. This decision aligns with typical governance practices for ASX-listed companies, and the board does not currently plan to appoint a replacement director.
Wellnex Life Limited has announced the cessation of Zlatko (Zack) Bozinovski as a director of the company, effective October 21, 2025. This change in the board of directors may impact the company’s governance and strategic direction, as Bozinovski held significant interests in the company, including 73,812 fully paid ordinary shares and an additional 667,473 shares through ZLJ Pty Ltd.
The most recent analyst rating on (AU:WNX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life Limited, a company listed on the ASX and AIM, announced the resignation of Mr. Zack Bozinovski as Director and CEO. During the transition period, Executive Chairman Mr. Ash Vesali will manage the company’s daily operations while a search for a new CEO is underway. Additionally, the company has agreed on a repayment schedule for a loan of A$2.3 million from Mr. Bozinovski and his wife, with full repayment due by April 2026.
The most recent analyst rating on (AU:WNX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life Limited, a company listed on ASX and AIM, has announced the resignation of Mr. Zack Bozinovski as Director and Chief Executive Officer. During the transition period, Executive Chairman Mr. Ash Vesali will manage the company’s operations while a new CEO is sought. Additionally, the company has agreed on a repayment schedule for a loan of A$2.3 million received from Mr. Bozinovski and his wife, with full repayment due by April 2026.
The most recent analyst rating on (AU:WNX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life Ltd has announced a strategic update under the leadership of new Executive Chairman Ash Vesali, focusing on a two-pillar strategy to enhance shareholder value through profitable growth. The company plans to prioritize its Pain Away brand and expand its contract manufacturing operations while deprioritizing non-core assets. A targeted cost reduction program is expected to deliver over $1 million in annualized savings, positioning Wellnex for sustained positive cash flow and profit.
The most recent analyst rating on (AU:WNX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life Limited reported a decrease in sales and cash receipts for Q1 FY26, primarily due to delayed IP licensing revenue. The company secured additional debt funding and is undergoing an internal review to enhance operational efficiencies and cost savings. Wellnex is exiting the medicinal cannabis market, which contributed minimally to revenue, to focus on more profitable areas.
The most recent analyst rating on (AU:WNX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life Ltd has announced the issuance of 847,826 unquoted options, each exercisable at A$1.40 and expiring on March 30, 2026. This move is likely to impact the company’s financial strategy and market positioning by potentially increasing its capital and providing more flexibility in its financial operations.
The most recent analyst rating on (AU:WNX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life Limited has issued over two million fully paid ordinary shares as part of a share placement to fulfill various agreements and corporate service mandates related to capital markets transactions, including its UK IPO. This strategic move aims to strengthen the company’s financial position and enhance its investor relations, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (AU:WNX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life Ltd has announced the issuance of 2,183,948 ordinary fully paid securities, which are to be quoted on the ASX. These shares are issued in lieu of cash for various agreements and corporate services mandates related to capital markets transactions, including the company’s UK IPO, indicating a strategic move to enhance its financial operations and investor relations.
The most recent analyst rating on (AU:WNX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life Limited has announced the appointment of Mr. Ash Vesali as the interim Executive Chairman for up to six months, effective immediately. This strategic move is intended to accelerate the company’s strategic goals and provide executive direction, while maintaining board independence with Mr. Eric Jiang as the Senior Independent Director.
Wellnex Life Limited reported a 40.5% increase in revenue for FY25, reaching A$23.6 million, driven by the full-year contribution from its Pain Away brand. Despite a net loss of A$15.6 million, the company improved its gross margin in the second half of the year through a refined trade investment strategy. The dual listing on the AIM Market and associated capital raising helped settle significant financial obligations, positioning Wellnex for future growth. The company aims to enhance revenue and margins in FY26 by leveraging its leading Pain Away brand and expanding contract manufacturing partnerships.
Wellnex Life Limited has expanded its market reach by receiving an initial order from Haleon plc for its TGA registered Liquid Paracetamol and Ibuprofen softgel for the UAE, marking the fourth national market entry after Australia, New Zealand, and the UK. This new agreement is expected to generate additional revenue for Wellnex Life in the current financial year, supporting its market forecasts and validating its strategic focus on innovative consumer healthcare products. The company has also secured confirmed purchase orders worth approximately $4.6 million since July 2025, further strengthening its financial outlook.
The most recent analyst rating on (AU:WNX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life Limited has announced the appointment of Ash Vesali as a director, effective from September 18, 2025. The initial director’s interest notice reveals that Vesali currently holds no securities in the company, indicating a fresh start in his role without existing financial interests in Wellnex Life Limited.
The most recent analyst rating on (AU:WNX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life Limited has appointed Ash Vesali as the new Non-Executive Chairman of its Board, effective immediately. This appointment follows the completion of due diligence by the company’s Nominated Advisor on AIM, signaling a strategic move to strengthen its leadership and potentially enhance its market position.
The most recent analyst rating on (AU:WNX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life Limited has expanded its financing facility with Reach Wholesale, securing an additional loan of up to A$2.5 million to support its growth. The facility, secured over the assets of key subsidiaries, offers a 24-month term with a 14% interest rate. The immediate drawdown of A$1.31 million will address long-term obligations and general working capital, with further funds contingent on Reach’s approval. This financial move is aimed at providing Wellnex Life with the flexibility needed to continue its business expansion and maintain its competitive edge in the healthcare industry.
The most recent analyst rating on (AU:WNX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life Limited has appointed Storelink Sales Limited as its distribution partner to expand its innovative brands into the New Zealand market. This strategic move follows the successful relaunch of its Pain Away brand and aims to capitalize on grocery and pharmacy channel opportunities in New Zealand. The collaboration with Storelink is expected to enhance brand awareness and drive growth in regional markets, aligning with Wellnex Life’s broader strategy to expand its market presence beyond Australia.
The most recent analyst rating on (AU:WNX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life Limited has announced the cessation of Andrew Vidler as a director, effective from September 15, 2025. This change in the board of directors may impact the company’s governance and strategic direction, as Vidler’s departure involves a transfer of interest in 17,858 fully paid ordinary shares to his spouse, Caren Lee Vidler.
The most recent analyst rating on (AU:WNX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life Limited has announced the resignation of Mr. Andrew Vidler from his roles as Independent Non-Executive Director and interim Non-executive Chair to focus on other business interests. The company has previously announced the appointment of Ash Vesali as the new Non-executive Chairman, pending due diligence. This leadership change is part of Wellnex’s strategy to strengthen its governance and potentially enhance its market positioning.
The most recent analyst rating on (AU:WNX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life Limited has announced the appointment of Ash Vesali as the new Non-Executive Chairman, succeeding Andrew Vidler, who will remain on the board as an Independent Non-Executive Director. Vesali brings over 20 years of experience in manufacturing and consulting, with a focus on strategy, governance, and performance improvement. His appointment is expected to guide Wellnex through its next growth phase, emphasizing the expansion of its Pain Away brand and contract manufacturing partnerships. This strategic move aims to bolster Wellnex’s market position and shareholder confidence.
The most recent analyst rating on (AU:WNX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life Limited reported a 40.4% increase in total revenue for FY25, reaching $23.6 million, primarily driven by its brands, including Pain Away. Despite a total loss of $15.6 million due to non-cash and one-off expenses, the company’s normalised EBITDA loss improved by 57% to $2.2 million. The dual listing on the AIM market of the London Stock Exchange strengthened Wellnex Life’s balance sheet, settling deferred considerations and convertible notes. The company plans to continue expanding its licensing opportunities and expects strong revenue growth in FY26, aiming to enhance shareholder value and operational profitability.
Wellnex Life Limited announced the resignation of its joint CEO and Managing Director, Mr. George Karafotias, who will step down immediately as a director but will assist with the transition over a three-month notice period. Mr. Zack Bozinovski will assume the role of sole CEO and MD, with no changes to his current employment terms. The company has agreed to repay a director loan of $705,000 plus interest to Mr. Karafotias within 90 days of his resignation. This leadership change could impact the company’s operations and stakeholder relations, as it continues its growth trajectory in the healthcare market.